• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    4/14/22 5:48:27 PM ET
    $ASLN
    $ATXI
    $CLXT
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASLN alert in real time by email

    Gainers

    • Kaleido Biosciences (NASDAQ:KLDO) stock increased by 10.3% to $0.32 during Thursday's after-market session. Today's trading volume for this security ended up closing at 14.2 million shares, which is 369.4 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $13.6 million.
    • NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares moved upwards by 9.28% to $0.95. At the close, NeuroBo Pharmaceuticals's trading volume reached 232.9K shares. This is 119.9% of its average volume over the last 100 days. The company's market cap stands at $25.3 million.
    • ASLAN Pharma (NASDAQ:ASLN) shares rose 9.14% to $0.82. The market value of their outstanding shares is at $57.1 million.
    • Renalytix (NASDAQ:RNLX) stock moved upwards by 7.87% to $6.3. The company's market cap stands at $235.4 million.
    • Calyxt (NASDAQ:CLXT) stock rose 6.06% to $0.7. The company's market cap stands at $29.9 million.
    • aTyr Pharma (NASDAQ:LIFE) shares increased by 6.06% to $5.25. The market value of their outstanding shares is at $145.9 million.

    Losers

    • Nektar Therapeutics (NASDAQ:NKTR) shares fell 22.1% to $4.8 during Thursday's after-market session. Nektar Therapeutics's trading volume hit 1.3 million shares by close, accounting for 41.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $894.1 million.
    • InVivo Therapeutics Hldg (NASDAQ:NVIV) stock declined by 8.95% to $0.27. This security traded at a volume of 80.1K shares come close, making up 15.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $9.4 million.
    • Evoke Pharma (NASDAQ:EVOK) stock fell 8.36% to $0.35. The market value of their outstanding shares is at $11.6 million.
    • Avenue Therapeutics (NASDAQ:ATXI) stock declined by 6.64% to $0.47. The company's market cap stands at $10.3 million.
    • Galectin Therapeutics (NASDAQ:GALT) shares declined by 6.33% to $1.63. This security traded at a volume of 519.1K shares come close, making up 525.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $96.7 million.
    • Immunogen (NASDAQ:IMGN) shares decreased by 5.43% to $5.06. The company's market cap stands at $1.1 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ASLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASLN
    $ATXI
    $CLXT
    $EVOK

    CompanyDatePrice TargetRatingAnalyst
    Nektar Therapeutics
    $NKTR
    3/17/2026Buy
    TD Cowen
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$33.00Buy
    Goldman
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$18.00Outperform
    Robert W. Baird
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$21.00Mkt Outperform
    Citizens
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$20.00Overweight
    Barclays
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$23.00Buy
    Deutsche Bank
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$13.00Overweight
    Analyst
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$15.00Buy
    Citigroup
    More analyst ratings

    $ASLN
    $ATXI
    $CLXT
    $EVOK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eldred Kary bought $810 worth of shares (300 units at $2.70), increasing direct ownership by 0.46% to 65,682 units (SEC Form 4)

    4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)

    2/9/26 4:25:19 PM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Botha Roelof bought $4,949,975 worth of shares (260,525 units at $19.00), converted options into 12,000,124 shares and returned 12,000,124 shares to the company (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 6:36:37 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Wheeler William J bought $4,949,975 worth of shares (260,525 units at $19.00), increasing direct ownership by 2,481% to 271,025 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:49:26 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $ASLN
    $ATXI
    $CLXT
    $EVOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

    SAN FRANCISCO, March 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata have been accepted for two oral presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31, 2026, in Denver, CO. Rezpegaldesleukin is a novel first-in-class regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions. Rezpegaldesleukin wo

    3/20/26 10:00:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.

    NORCROSS, Ga., March 17, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced it has appointed Henry Brem, M.D., as an independent director to its Board of Directors. Dr. Brem is an internationally recognized neurosurgeon-scientist and leader in translational medicine. He serves as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and previously served as Director of the Department of Neurosurgery and Neurosurgeon-in-Chief at The Johns Hopkins Medical Institutions. He is also Co-Director of the Brain Cancer Program at the Sidn

    3/17/26 8:00:00 AM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

    SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the fourth quarter ended December 31, 2025. Cash and investments in marketable securities on December 31, 2025 were $245.8 million as compared to $269.1 million on December 31, 2024. Cash and investments at December 31, 2025 excludes net proceeds of approximately $432 million from the $460 million secondary offering completed by the Company in February 2026, and also excludes net proceeds of $44 million from sales of shares in February and March 2026 under the Com

    3/12/26 4:15:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $ATXI
    $CLXT
    $EVOK
    SEC Filings

    View All

    Galectin Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)

    3/17/26 7:50:19 AM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

    3/12/26 4:45:08 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Nektar Therapeutics

    SCHEDULE 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    3/6/26 10:05:20 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $ATXI
    $CLXT
    $EVOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Brem Henry

    4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)

    3/17/26 9:46:55 AM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Brem Henry claimed no ownership of stock in the company (SEC Form 3)

    3 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)

    3/17/26 9:46:24 AM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief R&D Officer Zalevsky Jonathan sold $13,140 worth of shares (180 units at $73.00), decreasing direct ownership by 0.84% to 21,174 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    2/20/26 7:10:29 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $ATXI
    $CLXT
    $EVOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Nektar Therapeutics

    TD Cowen initiated coverage of Nektar Therapeutics with a rating of Buy

    3/17/26 7:57:51 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Ethos Technologies with a new price target

    Goldman initiated coverage of Ethos Technologies with a rating of Buy and set a new price target of $33.00

    2/23/26 8:37:19 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Robert W. Baird initiated coverage on Ethos Technologies with a new price target

    Robert W. Baird initiated coverage of Ethos Technologies with a rating of Outperform and set a new price target of $18.00

    2/23/26 8:37:19 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $ASLN
    $ATXI
    $CLXT
    $EVOK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 26, 2024 - FDA Roundup: March 26, 2024

    For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of

    3/26/24 3:38:14 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ELAHERE issued to IMMUNOGEN INC

    Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:

    3/22/24 1:48:21 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ELAHERE issued to IMMUNOGEN INC

    Submission status for IMMUNOGEN INC's drug ELAHERE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification:

    11/15/22 5:01:07 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $ATXI
    $CLXT
    $EVOK
    Leadership Updates

    Live Leadership Updates

    View All

    Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.

    NORCROSS, Ga., March 17, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced it has appointed Henry Brem, M.D., as an independent director to its Board of Directors. Dr. Brem is an internationally recognized neurosurgeon-scientist and leader in translational medicine. He serves as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and previously served as Director of the Department of Neurosurgery and Neurosurgeon-in-Chief at The Johns Hopkins Medical Institutions. He is also Co-Director of the Brain Cancer Program at the Sidn

    3/17/26 8:00:00 AM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors

    AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. Wheeler to its Board of Directors. Mr. Wheeler, a seasoned executive with deep expertise across insurance, retirement services, and investment banking, joins Ethos' distinguished board, further strengthening Ethos' governance and strategic guidance as the company continues its rapid growth and innovation. Mr. Wheeler brings more than three decades of leadership experience in the financial services industry. He most recently served as Vice Chairman of Athene Holding Ltd. (NYSE:ATH), a leadin

    7/30/25 11:00:00 AM ET
    $EVR
    $LIFE
    $ATH
    Investment Managers
    Finance
    Specialty Insurers
    Life Insurance

    $ASLN
    $ATXI
    $CLXT
    $EVOK
    Financials

    Live finance-specific insights

    View All

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    Records full-year revenue of $387.6 million, growing 52% year-over-yearAchieves Net Income of $24.6 million and Adjusted EBITDA of $25.8 million in Q4, reflecting a 22% margin and a 23% Adjusted EBITDA marginDelivers third consecutive year of revenue growth greater than 50% AUSTIN, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. "We delivered a strong close to 2025 with 65% year-over-year revenue growth in Q4," said Peter Colis, CEO and Co-Founder of Ethos. "Our financial resul

    2/25/26 4:05:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

    71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively Meaningful improvement in responses observed across key efficacy endpoints at week 52 with both monthly and quarterly dosing, including an up to 5-fold increase in EASI-100 response rates Favorable safety profile consistent with previously reported results for rezpegaldesleukin Durability of maintained response rates supports advancement to pivotal Phase 3 program evaluating both monthly and quarterly maintenance dosing Data validate novel first-in-class regulatory T-cell mechanism as a potential best-in-class immune-modulator Confere

    2/10/26 7:00:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $ATXI
    $CLXT
    $EVOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by NeuroBo Pharmaceuticals Inc.

    SC 13G - NeuroBo Pharmaceuticals, Inc. (0001638287) (Subject)

    11/14/24 3:34:00 PM ET
    $NRBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avenue Therapeutics Inc.

    SC 13G - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/14/24 3:22:45 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $ATXI
    $CLXT
    $EVOK
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Galectin Therapeutics Inc. on Jun 20

    Recently, on June 20, 2024, Galectin Therapeutics Inc. saw an insider purchase by Director Freeman Kevin D. He bought $5,950 worth of shares, which amounted to 2,500 units at a price of $2.38 per share. This transaction increased his direct ownership by 10% to 28,469 units, as reported in the SEC Form 4. It's essential to analyze this insider purchase in the context of previous transactions within the company. On February 7, 2024, Uihlein Richard E was granted 23,256 shares, increasing his direct ownership by 0.23% to 10,268,751 units. Similarly, on the same date, Zordani Richard A. Jr. filed an SEC Form 4. Continuing the trend, a new insider, Carson Benjamin Sr, filed an SEC Form 3 on Febr

    6/20/24 6:44:03 PM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care